17 studies found for:    Open Studies | "Hemorrhagic Fever, Ebola"
Show Display Options
Rank Status Study
1 Recruiting Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo
2 Recruiting Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
3 Recruiting Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
4 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo
5 Not yet recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
6 Not yet recruiting Multiple Treatments for Ebola Virus Disease (EVD)
Condition: Ebola Virus Disease
Interventions: Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
7 Recruiting Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen
Condition: Ebola Virus Survivor
Intervention: Drug: Favipiravir
8 Recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
9 Recruiting Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
Condition: Ebola Virus Disease
Intervention: Procedure: Convalescent Plasma Treatment
10 Recruiting GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Condition: Persistent Ebola Virus
Interventions: Drug: GS-5734;   Other: Placebo Comparator
11 Recruiting Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2
Condition: Healthy
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Menveo;   Biological: Placebo
12 Recruiting Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Condition: Ebola Vaccine
Interventions: Biological: INO-4201;   Biological: INO-4202;   Biological: INO-4212;   Biological: INO-4212 + INO-9012;   Biological: INO-4201 + INO-9012
13 Recruiting A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
Condition: Healthy
Interventions: Biological: MVA-BN-Filo;   Biological: Ad26.ZEBOV;   Biological: Placebo
14 Not yet recruiting Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure
Condition: Healthy Volunteers
Intervention: Drug: rVSVdeltaG-ZEBOV GP (2X 107 pfu/mL)
15 Recruiting A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
Condition: Healthy
Interventions: Biological: MVA-BN-Filo;   Biological: Ad26. ZEBOV;   Other: Placebo
16 Recruiting A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants
Condition: Healthy
Interventions: Biological: Ad26.ZEBOV 5*10^10 viral particles (vp);   Biological: Ad26.ZEBOV 2*10^10 (vp);   Biological: Ad26.ZEBOV 0.8*10^10 (vp);   Biological: MVA‐BN‐Filo 1*10^8 Infectious Unit [Inf. U.];   Biological: MVA‐BN‐Filo 5*10^7 Inf. U.;   Biological: Placebo
17 Recruiting Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers
Condition: Healthy
Intervention: Drug: ZMAPP

Indicates status has not been verified in more than two years